Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 305

The DOI matches its Crossref record.

Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure

Open access
Hirschberg, Raimund, Kopple, Joel, Lipsett, Pamela, Benjamin, Ernest, Minei, Joseph, Albertson, Timothy, Munger, Mark, Metzler, Michael, Zaloga, Gary, Murray, Michael, Lowry, Stephen, Conger, John, Mckeown, Wade, O'Shea, Michael, Baughman, Robert, Wood, Kenneth, Haupt, Marilyn, Kaiser, Roger, Simms, Hank, Warnock, David, Summer, Warren, Hintz, Raymond, Myers, Brian, Haenftling, Kathrine, Capra, William, Pike, Marilyn, Guler, Hans-Peter·1999·Kidney International

Abstract

BACKGROUND: Patients with acute renal failure (ARF) have high morbidity and mortality rates, particularly if they have serious comorbid conditions. Several studies indicate that in rats with ARF caused by ischemia or certain nephrotoxins, insulin-like growth factor-I (IGF-I) enhances the recovery of renal function and suppresses protein catabolism. METHODS: Our objective was to determine whether injections of recombinant human IGF-I (rhIGF-I) would enhance the recovery of renal function and is safe in patients with ARF. The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals. Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients). The most common causes of ARF in the rhIGF-I and placebo groups were, respectively, sepsis (37 and 35% of patients) and hypotension or hemodynamic shock (42 and 27% of patients). At baseline, the mean (+/- SD) APACHE II scores in the rhIGF-I and placebo-treated groups were 24 +/- 5 and 25 +/- 8, respectively. In the rhIGF-I and placebo groups, the mean (median) urine volume and urinary iothalamate clearances (glomerular filtration rate) were 1116 +/- 1037 (887) and 1402 +/- 1183 (1430) ml/24 hr and 6.4 +/- 5.9 (4.3) and 8.7 +/- 7.2 (4.4) ml/min and did not differ between the two groups. Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days. Injections were started within six days of the onset of ARF. The primary end-point was a change in glomerular filtration rate from baseline. Other end points included changes from baseline in urine volume, creatinine clearance and serum urea, creatinine, albumin and transferrin, frequency of hemodialysis or ultrafiltration, and mortality rate. RESULTS: During the treatment period, which averaged 10.7 +/- 4.1 and 10.6 +/- 4.5 days in the rhIGF-I and placebo groups, there were no differences in the changes from baseline values of the glomerular filtration rate, creatinine clearance, daily urine volume, or serum urea nitrogen, creatinine, albumin or transferrin. In patients who did not receive renal replacement therapy, there was also no significant difference in serum creatinine and urea between the two groups. Twenty patients in the rhIGF-I group and 17 placebo-treated patients underwent dialysis or ultrafiltration. Twelve rhIGF-I-treated patients and 12 placebo-treated patients died during the 28 days after the onset of treatment. CONCLUSIONS: rhIGF-I does not accelerate the recovery of renal function in ARF patients with substantial comorbidity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1523-1755.1999.00463.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 305

Metadata

Authors
Hirschberg, R., Kopple, J., Lipsett, P., Benjamin, E., Minei, J., Albertson, T., Munger, M., Metzler, M., Zaloga, G., Murray, M., Lowry, S., Conger, J., Mckeown, W., O'Shea, M., Baughman, R., Wood, K., Haupt, M., Kaiser, R., Simms, H., Warnock, D., Summer, W., Hintz, R., Myers, B., Haenftling, K., Capra, W., Pike, M., & Guler, H.-P.
Venue
Kidney International
Publisher
Elsevier BV
Published
1999-06
Volume
55
Issue
6
Pages
2423-2432
ISSN
0085-2538 (ISSN-L)
OpenAlex
W2048489506
Cited by
305
References
0
FWCI
10.84
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. https://app.cochat.ai/papers/10.1046/j.1523-1755.1999.00463.x
The paper
Hirschberg, R., Kopple, J., Lipsett, P., Benjamin, E., Minei, J., Albertson, T., Munger, M., Metzler, M., Zaloga, G., Murray, M., Lowry, S., Conger, J., Mckeown, W., O'Shea, M., Baughman, R., Wood, K., Haupt, M., Kaiser, R., Simms, H., . . . Guler, H.-P. (1999). Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney International. https://doi.org/10.1046/j.1523-1755.1999.00463.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.